openPR Logo
Press release

Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H1 2017 : Pharmaceuticals Industry Research Report - MRH

06-29-2017 05:19 PM CET | Health & Medicine

Press release from: Business and Banking Research Reports [MRH]

Market Research Hub

Market Research Hub

According to the report “Tumor Necrosis Factor Receptor Superfamily Member 10B Pipeline Review H1 2017” outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Request For Free Sample @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1196631

Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) or Death receptor 5 (DR5) is a protein encoded by TNFRSF10B. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL) and thus transduces cell death signal and induces cell apoptosis. It promotes the activation of NF-kappa-B.

According to the recently published report 'Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H1 2017'; Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes.

It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 3, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology and Immunology which include indications Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colorectal Cancer, Glioma, Lymphoma, Melanoma, Metastatic Colorectal Cancer, Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma and Rheumatoid Arthritis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics

Browse Full Report With TOC @ http://www.marketresearchhub.com/report/tumor-necrosis-factor-receptor-superfamily-member-10b-death-receptor-5-or-tnf-related-apoptosis-inducing-ligand-receptor-2-or-trail-receptor-2-or-dr5-or-cd262-or-tnfrsf10b-pipeline-review-h1-2017-report.html

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1196631

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/
Read More Related News: https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H1 2017 : Pharmaceuticals Industry Research Report - MRH here

News-ID: 602044 • Views: 162

More Releases from Business and Banking Research Reports [MRH]

Russian Accident and health insurance industry Comprehensive Outlook, Key Trends …
Market Research Hub (MRH) added a new research report to its vast database titled “Accident and Health insurance in Russia, Key Trends and Opportunities to 2020” which provides a detailed outlook by product category for the Russian accident and health insurance segment, and a comparison of the Russian insurance industry with its regional counterparts. Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1328144 It provides key performance indicators such as written premium, incurred loss, loss
Russian Life Insurance industry Comprehensive Outlook, Key Trends and Opportunit …
Market Research Hub (MRH) added a new research report to its vast database titled “Life Insurance in Russia, Key Trends and Opportunities to 2020” which provides a detailed outlook by product category for the Russian life insurance segment, and a comparison of the Russian Life insurance industry with its regional counterparts. Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1328142 The report provides key performance indicators such as written premium, incurred loss, loss ratio, commissions
Latvian Insurance Industry Market Trends, Drivers, Challenges, Opportunities Unt …
Market Research Hub (MRH) has included a new research report titled “The Insurance Industry in Latvia Key Trends and Opportunities to 2021”, which provides values for key performance indicators such as written premium, incurred loss, loss ratio, commissions and expenses, combined ratio, total assets, total investment income and retentions during the review period (2011-2015) and forecast period (2016-2020). Request Free Sample Report @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1328139 The report also analyzes distribution channels operating in
EMEA Gusseted Bags Market Outlook Offers Analysis on Emerging Trends and Growth …
A fresh report has been added to the wide database of Market Research Hub (MRH). The research study is titled “EMEA Gusseted Bags Market Report” which encloses important data about the production, consumption, revenue and market share, merged with information related to the market scope and product overview. The report anticipates that the sector for Retail would rise at a positive CAGR during the period 2017-2022. Request For Free Sample -

All 5 Releases


More Releases for Receptor

Interleukin Receptor Modulators Therapeutics - Pipeline Analysis 2019
Interleukin receptors are a group of cytokine receptors that are expressed by leukocytes. Interleukin receptors play an important role in the functioning of the immune system. However, with complete knowledge of their role in pathogenesis of different diseases from allergic reactions to autoimmune disorders and even cancer makes these interleukin receptors an attractive target among different available treatment modalities. Download the sample report @ https://www.pharmaproff.com/request-sample/1204 Immune-modulatory role of interleukins as well
Tumor Necrosis Factor Receptor
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Tumor Necrosis Factor - Pipeline Review, H2 2017” Tumor Necrosis Factor Overview Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed
Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1) …
"The Report Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1)-Lysophosphatidic acid receptor 1 is a G protein-coupled receptor that binds the lipid signaling molecule lysophosphatidic acid (LPA). Lysophosphatidic acid (LPA) receptor belongs to a group known as
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Gh …
"The Report Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)-Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin. Ghrelin is
Estrogen Receptor Market Pipeline Review, H2 2017
"The Report Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) pipeline Target constitutes close to 22 molecules.
Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Pipe …
"The Report Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" According to the recently published report 'Prostaglandin E2 Receptor EP4 Subtype Pipeline Review, H2 2017'; Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 11 molecules. Out of which approximately 10